ROCKVILLE, Md., Feb. 8, 2012 /PRNewswire/ -- MMG, a global clinical trial patient recruitment group and part of Ketchum, today announced the addition of Chris Middleton as vice president of technology. Middleton oversees all new technology products and application, service, and infrastructure development. He will provide leadership and strategic direction for MMG's expanding portfolio of technology-based patient recruitment efforts.
"Welcoming a technology expert of Chris's caliber to our accomplished leadership team underscores MMG's commitment to better enable individuals to connect with clinical trials through technology," said John Benbrook, CEO of MMG. "Chris's passion for developing novel technology solutions that bridge gaps between patients and the services they need is perfectly suited for achieving MMG's aggressive goals for innovating and meeting our clients' needs."
Middleton is a software industry veteran with an impressive track record in complex software development across the healthcare, privacy, biometrics and enterprise integration industries, both in the United States and internationally. In addition to serving as a software architect and technology manager for companies such as CGI-AMS, Software AG, Deutsche Post DHL and Daon, Chris has held leadership positions for software startups and also founded Scaled Objects in 2007.
"I am thrilled to bring new patient recruitment technology solutions to life with MMG, a company with a strong commitment to improving healthcare through the acceleration of medical research," said Middleton. "It is a great time to be a part of such a skilled organization, and I am quickly working to further its innovation initiatives and achieve improved trial engagement and recruitment results on behalf of our clients."
Middleton is a graduate of Virginia Tech, a resident of Alexandria, Va., and a passionate technology futurist.
About MMG
MMG, a Ketchum company and part of the Omnicom Group (NYSE: OMC) family, is the premier global patient recruitment and retention organization. With experience in more than 70 countries and across a vast range of therapeutic areas, populations, and study types, MMG provides strategies specially crafted for study teams and patient populations while delivering the best return on investment for the sponsor.
SOURCE MMG